May 20th, 12:30 PM

Sustained Expression with Partial Correction of Neutrophil Defects 5 Years After Intramuscular rAAV1 Gene Therapy for Alpha-1 Antitrypsin Deficiency

Terence R. Flotte  
*University of Massachusetts Medical School*

Christian Mueller  
*University of Massachusetts Medical School*

Gwladys Gernoux  
*University of Massachusetts Medical School*

*See next page for additional authors*

Follow this and additional works at: [http://escholarship.umassmed.edu/cts_retreat](http://escholarship.umassmed.edu/cts_retreat)

Part of the [Congenital, Hereditary, and Neonatal Diseases and Abnormalities Commons](https://escholarship.umassmed.edu/collections/critical-care), [Genetic Processes Commons](https://escholarship.umassmed.edu/collections/clinical-genetics), [Genetics and Genomics Commons](https://escholarship.umassmed.edu/collections/clinical-genetics), [Respiratory Tract Diseases Commons](https://escholarship.umassmed.edu/collections/clinical-respiratory), and the [Therapeutics Commons](https://escholarship.umassmed.edu/collections/clinical-therapeutics)

Flotte, Terence R.; Mueller, Christian; Gernoux, Gwladys; Gruntman, Alisha; Chulay, Jeffrey D.; Knop, David R.; McElvaney, Noel G.; Campbell-Thompson, Martha; and Wilson, James M., "Sustained Expression with Partial Correction of Neutrophil Defects 5 Years After Intramuscular rAAV1 Gene Therapy for Alpha-1 Antitrypsin Deficiency" (2016). *UMass Center for Clinical and Translational Science Research Retreat*. 30.  
[http://escholarship.umassmed.edu/cts_retreat/2016/posters/30](http://escholarship.umassmed.edu/cts_retreat/2016/posters/30)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Presenter Information
Terence R. Flotte, Christian Mueller, Gwladys Gernoux, Alisha Gruntman, Jeffrey D. Chulay, David R. Knop, Noel G. McElvaney, Martha Campbell-Thompson, and James M. Wilson

Keywords
Alpha-one antitrypsin deficiency, adeno-associated virus, genetic disorder, emphysema

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.

This poster abstract is available at eScholarship@UMMS: http://escholarship.umassmed.edu/cts_retreat/2016/posters/30
SUSTAINED EXPRESSION WITH PARTIAL CORRECTION OF NEUTROPHIL DEFECTS 5 YEARS AFTER INTRAMUSCULAR rAAV1 GENE THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY.

Terence R Flotte\textsuperscript{1,2}, Christian Mueller\textsuperscript{1,2}, Gwladys Gernoux\textsuperscript{1}, Alisha M Gruntman\textsuperscript{1,3}, Jeffery Chulay\textsuperscript{4}, Dave Knop\textsuperscript{4}, Noel G McElvaney\textsuperscript{5}, Martha Campbell-Thompson\textsuperscript{6}, James M Wilson\textsuperscript{7}.

\textsuperscript{1}University of Massachusetts Medical School Horae Gene Therapy Center and \textsuperscript{2}Department of Pediatrics, \textsuperscript{3}Tufts Cummings School of Veterinary Medicine, \textsuperscript{4}Applied Genetic Technologies Corporation, \textsuperscript{5}Royal College of Surgeons of Ireland, \textsuperscript{6}University of Florida, \textsuperscript{7}University of Pennsylvania.

Alpha-1 antitrypsin (AAT) deficiency is a common monogenic disorder resulting in emphysema, which is currently treated with weekly infusions of protein replacement. We previously reported achieving plasma wild-type (M) AAT concentrations at 2.5-3.8% of the therapeutic level at 1 year after intramuscular (IM) administration of $6 \times 10^{12}$ vg/kg of a recombinant adeno-associated virus serotype 1 (rAAV1)-AAT vector in AAT-deficient patients, with an associated regulatory T cell (Treg) response to AAV1 capsid epitopes in the absence of any exogenous immune suppression. Here, we report sustained expression at greater than 2% of the therapeutic level for 5 years after one-time treatment with rAAV1-AAT in an AAT-deficient patient from that study, with partial correction of neutrophil defects previously reported in AAT-deficient patients. There was also evidence of an active Treg response (FoxP3+, Helios+) and an exhausted cytotoxic T cell response (PD-1+, LAG-3+) to AAV1 capsid. These findings suggest that muscle-based AAT gene replacement is toleragenic and that very stable levels of M AAT may exert beneficial effects at lower concentrations than previously anticipated.

Contact: Alisha Gruntman, Alisha.Gruntman@umassmed.edu, 508-208-8327